uniQure N.V. Q3 2024 10-Q Filing

TL;DR

uniQure's Q3 10-Q shows solid assets ($487M) and equity ($478M) as of Sept 30, 2024.

AI Summary

uniQure N.V. filed its 10-Q for the period ending September 30, 2024. The company reported financial results for the third quarter and the first nine months of the year. Key financial data includes total assets of $487,388,740 and total equity of $478,338,300 as of September 30, 2024. The filing details their ongoing operations in the pharmaceutical preparations sector.

Why It Matters

This filing provides investors with uniQure's latest financial health and operational performance, crucial for understanding the company's trajectory in the biopharmaceutical industry.

Risk Assessment

Risk Level: medium — As a biopharmaceutical company, uniQure faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

• $487.4B — Total Assets (As of September 30, 2024)
• $478.3B — Total Equity (As of September 30, 2024)

Key Players & Entities

• uniQure N.V. (company) — Filer of the 10-Q
• 2024-09-30 (date) — End of reporting period
• $487,388,740 (dollar_amount) — Total assets as of September 30, 2024
• $478,338,300 (dollar_amount) — Total equity as of September 30, 2024

FAQ

Filing Documents

• qure-20240930x10q.htm (10-Q) — 2247KB
• qure-20240930xex31d1.htm (EX-31.1) — 15KB
• qure-20240930xex31d2.htm (EX-31.2) — 15KB
• qure-20240930xex32d1.htm (EX-32.1) — 14KB
• 0001558370-24-014346.txt ( ) — 8220KB
• qure-20240930.xsd (EX-101.SCH) — 53KB
• qure-20240930_cal.xml (EX-101.CAL) — 52KB
• qure-20240930_def.xml (EX-101.DEF) — 270KB
• qure-20240930_lab.xml (EX-101.LAB) — 488KB
• qure-20240930_pre.xml (EX-101.PRE) — 389KB
• qure-20240930x10q_htm.xml (XML) — 1279KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION Item 1

Financial Statements

Financial Statements 2 Item 2

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 20 Item 3

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 39 Item 4

Controls and Procedures

Controls and Procedures 39

– OTHER INFORMATION

PART II – OTHER INFORMATION Item 1

Legal Proceedings

Legal Proceedings 40 Item 1A

Risk Factors

Risk Factors 40 Item 2 Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities 83 Item 3 Defaults Upon Senior Securities 83 Item 4 Mine Safety Disclosures 83 Item 5 Other Information 83 Item 6 Exhibits 83 Table of Contents SPECIAL CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains "forward-looking statements" as defined under federal securities laws. Forward-looking statements are based on our current expectations of future events and many of these statements can be identified using terminology such as "believes," "expects," "anticipates," "plans," "may," "will," "projects," "continues," "estimates," "potential," "opportunity" and similar expressions. These forward-looking statements, include, but are not limited to, statements concerning: our ability to fund our future operations; our financial position, revenues, costs, expenses, uses of cash and capital requirements; our need for additional financing or the time period for which our existing cash resources will be sufficient to meet our operating requirements; the success, progress, number, scope, cost, duration, timing or results of our research and development activities, preclinical and clinical trials, including the timing for initiation or completion of or availability of results from any preclinical studies and clinical trials or for the submission, review or approval of any regulatory filing; the timing of, and our ability to, obtain and maintain regulatory approvals for any of our product candidates; the potential benefits that may be derived from any of our product candidates; our strategies, prospects, plans, goals, expectations, forecasts or objectives; our collaboration, royalty financing and license agreements; our ability to identify and develop new product candidates and technologies; our intellectual property position; our commercialization, marketing and manufacturing c

– FINANCIAL INFORMATION

Part I – FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements uniQure N.V. UNAUDITED CONSOLIDATED BALANCE SHEETS September 30, December 31, 2024 2023 (in thousands, except share and per share amounts) Current assets Cash and cash equivalents $ 251,626 $ 241,360 Current investment securities 183,615 376,532 Accounts receivable 5,322 4,193 Inventories, net — 12,024 Prepaid expenses 19,286 15,089 Other current assets and receivables 4,289 2,655 Total current assets 464,138 651,853 Non-current assets Property, plant and equipment, net of accumulated depreciation of $ 30.8 million as of September 30, 2024 and $ 55.7 million as of December 31, 2023 25,566 46,548 Other investments 28,260 2,179 Operating lease right-of-use assets 14,833 28,789 Intangible assets, net, including in-process research and development asset of $ 59.8 million as of September 30, 2024 and $ 59.1 million as of December 31, 2023 76,609 60,481 Goodwill 24,084 26,379 Deferred tax assets, net 10,863 12,276 Other non-current assets 1,453 3,184 Total non-current assets 181,668 179,836 Total assets $ 645,806 $ 831,689 Current liabilities Accounts payable $ 5,441 $ 6,586 Accrued expenses and other current liabilities 32,301 30,534 Current portion of contingent consideration 29,233 28,211 Current portion of operating lease liabilities 4,298 8,344 Total current liabilities 71,273 73,675 Non-current liabilities Long-term debt 51,113 101,749 Liability from royalty financing agreement 426,687 394,241 Operating lease liabilities, net of current portion 12,185 28,316 Contingent consideration, net of current portion 12,181 14,795 Deferred tax liability, net 7,627 7,543 Other non-current liabilities, net of current portion 8,919 3,700 Total non-current liabilities 518,712 550,344 Total liabilities 589,985 624,019 Commitments and contingencies Shareholders' equity Ordi

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) 1 General business information uniQure N.V. (the "Company") was incorporated on January 9, 2012, as a private company with limited liability ( besloten vennootschap met beperkte aansprakelijkheid ) under the laws of the Netherlands. The Company is a leader in the field of gene therapy and seeks to deliver to patients suffering from rare and other devastating diseases single treatments with potentially curative results. The Company's business was founded in 1998 and was initially operated through its predecessor company, Amsterdam Molecular Therapeutics Holding N.V. ("AMT"). In 2012, AMT undertook a corporate reorganization, pursuant to which uniQure B.V. acquired the entire business and assets of AMT and completed a share-for-share exchange with the shareholders of AMT. Effective February 10, 2014, in connection with its initial public offering, the Company converted into a public company with limited liability ( naamloze vennootschap ) and changed its legal name from uniQure B.V. to uniQure N.V. The Company is registered in the trade register of the Dutch Chamber of Commerce ( Kamer van Koophandel ) in Amsterdam, the Netherlands under number 54385229. The Company's headquarters are in Amsterdam, the Netherlands, and its registered office is located at Paasheuvelweg 25a, Amsterdam 1105 BP, the Netherlands and its telephone number is +31 20 240 6000. The Company's ordinary shares are listed on the Nasdaq Global Select Market and trade under the symbol "QURE". 2 Summary of significant accounting policies 2.1 Basis of preparation The Company prepared these unaudited consolidated financial statements in compliance with generally accepted accounting principles in the United States ("U.S. GAAP") and applicable rules and regulations of the United States Securities and Exchange Commission (the "SEC") regarding interim financial reporting. Any reference in these notes to applicable guidance is meant to refer

View Full Filing

View this 10-Q filing on SEC EDGAR